Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Zacks Investment Research on MSN
Can Eli Lilly sustain its obesity momentum as newer players emerge?
Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its ...
Corbus Pharmaceuticals Holdings, Inc. ( CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data December 11, 2025 8:00 AM EST ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback